BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 29279269)

  • 1. Renin angiotensin-aldosterone system (RAAS) blockers usage among type II diabetes mellitus patients-A Retrospective Study.
    Ng YP; Balasubramanian GP; Heng YP; Kalaiselvan M; Teh YW; Cheong KM; Hadi MFBA; Othman RB
    Diabetes Metab Syndr; 2018 May; 12(3):305-308. PubMed ID: 29279269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The rate of progression of type 2 diabetes mellitus to end stage renal disease - A single centred retrospective study from Malaysia.
    Ng YP; Ahmed R; Ooi GS; Lau CY; Balasubramanian GP; Yap CH
    Diabetes Metab Syndr; 2018 Nov; 12(6):1025-1030. PubMed ID: 30168425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of chronic usage of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on contrast-induced nephropathy in low-risk patients [corrected].
    Barış N; Özpelit E; Doğan NB; Kangül H; Gül S; Akdeniz B; Güneri S
    Anadolu Kardiyol Derg; 2013 May; 13(3):245-50. PubMed ID: 23261803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin receptor blockers (ARB) outperform angiotensin-converting enzyme (ACE) inhibitors on ischemic stroke prevention in patients with hypertension and diabetes - A real-world population study in Taiwan.
    Pai PY; Muo CH; Sung FC; Ho HC; Lee YT
    Int J Cardiol; 2016 Jul; 215():114-9. PubMed ID: 27111172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined use of renin-angiotensin-aldosterone system-acting agents: a cross-sectional study.
    Farcas A; Leucuta D; Bucsa C; Mogosan C; Dumitrascu D
    Int J Clin Pharm; 2016 Dec; 38(6):1390-1397. PubMed ID: 27677980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of astragalus combined with renin-angiotensin-aldosterone system blockers in the treatment of stage III diabetic nephropathy: a systematic review and meta-analysis.
    Lin YQ; Yu F; Chen HJ; Deng YR; Lin J; Xu Y; Zheng X; Zhang JW; Liu JF
    Ren Fail; 2024 Dec; 46(2):2359033. PubMed ID: 38836372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renin-angiotensin system blockers and residual kidney function loss in patients initiating peritoneal dialysis: an observational cohort study.
    Shen JI; Saxena AB; Vangala S; Dhaliwal SK; Winkelmayer WC
    BMC Nephrol; 2017 Jun; 18(1):196. PubMed ID: 28623899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Renin-Angiotensin-Aldosterone System Inhibitors on Short-Term Mortality After Sepsis: A Population-Based Cohort Study.
    Hsu WT; Galm BP; Schrank G; Hsu TC; Lee SH; Park JY; Lee CC
    Hypertension; 2020 Feb; 75(2):483-491. PubMed ID: 31838905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
    Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
    Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renin Angiotensin Aldosterone System (RAAS): its biology and drug targets for treating diabetic nephropathy.
    Zain M; Awan FR
    Pak J Pharm Sci; 2014 Sep; 27(5):1379-91. PubMed ID: 25176370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention.
    Talbert RL
    J Am Pharm Assoc (2003); 2010; 50(5):e116-25. PubMed ID: 20833609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypertension: renin-angiotensin-aldosterone system alterations.
    Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH
    Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renin-angiotensin-aldosterone system blockers for heart failure with reduced ejection fraction or left ventricular dysfunction: Network meta-analysis.
    Xie W; Zheng F; Song X; Zhong B; Yan L
    Int J Cardiol; 2016 Feb; 205():65-71. PubMed ID: 26720043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of renin-angiotensin-aldosterone blockade by angiotensin-converting enzyme inhibitors or AT-1 blockers on frequency of contrast medium-induced nephropathy: a post-hoc analysis from the Dialysis-versus-Diuresis (DVD) trial.
    Kiski D; Stepper W; Brand E; Breithardt G; Reinecke H
    Nephrol Dial Transplant; 2010 Mar; 25(3):759-64. PubMed ID: 19903660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual Blockade of the Renin-angiotensin-aldosterone System in Type 2 Diabetic Kidney Disease.
    Feng YH; Fu P
    Chin Med J (Engl); 2016 Jan; 129(1):81-7. PubMed ID: 26712437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reporting of the estimated glomerular filtration rate was associated with increased use of angiotensin-converting enzyme inhibitors and angiotensin-II receptor blockers in CKD.
    Jain AK; Cuerden MS; McLeod I; Hemmelgarn B; Akbari A; Tonelli M; Quinn RR; Oliver MJ; Garg AX
    Kidney Int; 2012 Jun; 81(12):1248-53. PubMed ID: 22437415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial.
    Fernandez Juarez G; Luño J; Barrio V; de Vinuesa SG; Praga M; Goicoechea M; Cachofeiro V; Nieto J; Fernández Vega F; Tato A; Gutierrez E;
    Am J Kidney Dis; 2013 Feb; 61(2):211-8. PubMed ID: 22939518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Renin-Angiotensin-Aldosterone System Blockade in Patients with End-Stage Renal Disease.
    Slomka T; Lennon ES; Akbar H; Gosmanova EO; Bhattacharya SK; Oliphant CS; Khouzam RN
    Am J Med Sci; 2016 Mar; 351(3):309-16. PubMed ID: 26992264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial long-term effect of aldosterone antagonist added to a traditional blockade of the renin-angiotensin-aldosterone system among patients with obesity and proteinuria.
    Morales E; Gutiérrez E; Caro J; Sevillano A; Rojas-Rivera J; Praga M
    Nefrologia; 2015; 35(6):554-61. PubMed ID: 26519114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of renin-angiotensin system blockade in patients with chronic kidney disease under specialist care. Retrospective cross-sectional study.
    Tylicki L; Jakubowska A; Lizakowski S; Świetlik D; Rutkowski B
    J Renin Angiotensin Aldosterone Syst; 2015 Mar; 16(1):145-52. PubMed ID: 25324423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.